Penumbra, Inc. PEN
321.72 USD +0.26 (+0.08%)
At closeNov 11, 2026, 4:44 PM EST
321.85 +0.13 +0.04%
After hours · Nov 11, 4:44 PM ET
320.28 Day range 322.24
278.10 52-week range 359.40
- YTD
- +3.48%
- 1 year
- +15.03%
News
benzinga.com Penumbra Q3 EPS $1.07 Misses $1.25 Estimate, Sales $410.145M Beat $403.345M Estimate Penumbra (NYSE:PEN) reported quarterly earnings of $1.07 per share which missed the analyst consensus estimate of $1.25 by 14.4 percent. This is a 10.31 percent increase over earnings of $0.97 per…
prnewswire.com Penumbra, Inc. Reports Third Quarter 2026 Financial Results ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
benzinga.com Penumbra Wins FDA Clearance For Lightning CAVT Technology To Treat Deep Vein Thrombosis, Backed By BOLT-DVT Trial Results BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and…
prnewswire.com Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT) BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective…
defenseworld.net Penumbra (NYSE:PEN) Stock Breaks Above 50-Day Moving Average – Should You Sell? Penumbra, Inc. (NYSE: PEN - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $321.17 and traded as high…
benzinga.com Penumbra Presents Results From Subset Analysis Of STORM-PE Randomized Controlled Trial At Vascular InterVentional Advances Meeting Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recoveryALAMEDA,…
prnewswire.com New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recovery ALAMEDA,…
zacks.com IART vs. PEN: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value…
defenseworld.net Penumbra (NYSE:PEN) Stock Price Breaks Below Fifty Day Moving Average – What’s Next? Penumbra, Inc. (NYSE: PEN - Get Free Report)'s stock price crossed below its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $321.74 and traded as low as…
zacks.com IART or PEN: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option…
zacks.com Reasons to Retain Penumbra Stock in Your Portfolio for Now PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.
zacks.com TFX vs. PEN: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
defenseworld.net Connor Clark & Lunn Investment Management Ltd. Buys New Position in Penumbra, Inc. $PEN Connor Clark and Lunn Investment Management Ltd. purchased a new position in shares of Penumbra, Inc. (NYSE: PEN) during the second quarter, according to its most recent 13F filing with the…
zacks.com TFX or PEN: Which Is the Better Value Stock Right Now? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued…
benzinga.com Incuvate Files Patent Infringement Lawsuit Against Penumbra Incuvate, LLC today announced that it has filed a patent-infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California.The lawsuit, filed August 19,…
zacks.com TFX vs. PEN: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity…- benzinga.com Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate Penumbra (NYSE:PEN) reported quarterly earnings of $0.88 per share which missed the analyst consensus estimate of $1.20 by 26.67 percent. This is a 23.48 percent decrease over earnings of $1.15 per…
prnewswire.com Penumbra, Inc. Reports Second Quarter 2026 Financial Results ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
defenseworld.net Bank of Nova Scotia Acquires 210,402 Shares of Penumbra, Inc. $PEN Bank of Nova Scotia boosted its stake in Penumbra, Inc. (NYSE: PEN) by 14,837.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission…
defenseworld.net California Public Employees Retirement System Increases Position in Penumbra, Inc. $PEN California Public Employees Retirement System lifted its stake in shares of Penumbra, Inc. (NYSE: PEN) by 25.1% during the undefined quarter, according to the company in its most recent filing with…
gurufocus.com THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care PR Newswire ALAMEDA, Cal
prnewswire.com THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care First and only CAVT device for stroke demonstrated high revascularization rates, short procedure times and low complication rates ALAMEDA, Calif., July 22, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:…
defenseworld.net Penumbra, Inc. $PEN Shares Sold by Bank of New York Mellon Corp Bank of New York Mellon Corp decreased its stake in shares of Penumbra, Inc. (NYSE: PEN) by 0.9% during the undefined quarter, according to the company in its most recent filing with the Securities…
marketbeat.com 3 Medical Device Stocks Giving Investors a Different Healthcare Play When investors think of the health care sector, most imagine the stability of pharmaceutical giants or the high-risk/high-reward profile of up-and-coming clinical stage drug developers. Medical…
zacks.com IQV vs. PEN: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Instruments sector have probably already heard of IQVIA Holdings (IQV) and Penumbra (PEN). But which of these two stocks is more attractive to value…
benzinga.com Penumbra Initiates FORWARD Trial To Collect Safety, Efficacy Data On Mechanical Thrombectomy Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will…- benzinga.com Evercore ISI Group Maintains Outperform on Penumbra, Lowers Price Target to $320 Evercore ISI Group analyst Vijay Kumar maintains Penumbra (NYSE:PEN) with a Outperform and lowers the price target from $335 to $320.
- benzinga.com RBC Capital Reiterates Sector Perform on Penumbra, Maintains $374 Price Target RBC Capital analyst Shagun Singh reiterates Penumbra (NYSE:PEN) with a Sector Perform and maintains $374 price target.
- benzinga.com Penumbra's THUNDERBOLT Gets FDA Clearance To Treat Acute Ischemic Stroke Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted…
benzinga.com Citigroup Maintains Neutral on Penumbra, Lowers Price Target to $350 Citigroup analyst Joanne Wuensch maintains Penumbra (NYSE:PEN) with a Neutral and lowers the price target from $374 to $350.- benzinga.com Evercore ISI Group Maintains Outperform on Penumbra, Lowers Price Target to $335 Evercore ISI Group analyst Vijay Kumar maintains Penumbra (NYSE:PEN) with a Outperform and lowers the price target from $345 to $335.
- benzinga.com Penumbra Q1 Adj. EPS $1.00 Misses $1.07 Estimate, Sales $374.758M Beat $371.104M Estimate Penumbra (NYSE:PEN) reported quarterly earnings of $1.00 per share which missed the analyst consensus estimate of $1.07 by 7.41 percent. This is a 0 percent increase over earnings of $1.00 per share…
benzinga.com 8 Stocks to Buy as Merger-Mania Takes Over Consolidation wave creates opportunities for patient investors. 8 sectors leading now are health, semiconductors, medical devices, and media.- benzinga.com Evercore ISI Group Maintains Outperform on Penumbra, Raises Price Target to $360 Evercore ISI Group analyst Vijay Kumar maintains Penumbra (NYSE:PEN) with a Outperform and raises the price target from $340 to $360.
benzinga.com Penumbra Q4 Earnings Assessment - benzinga.com Penumbra Q4 Adj. EPS $1.18 Beats $1.11 Estimate, Sales $385.385M Beat $366.795M Estimate Penumbra (NYSE:PEN) reported quarterly earnings of $1.18 per share which beat the analyst consensus estimate of $1.11 by 6.12 percent. This is a 38.82 percent increase over earnings of $0.85 per…
benzinga.com Price Over Earnings Overview: Penumbra 
benzinga.com Boston Scientific Advises Removal Of Certain AXIOS Stents After Deployment Issues Surface FDA is reviewing AXIOS stent delivery issues after Boston Scientific reported injuries and deaths, urging facilities to stop use and remove affected devices.
benzinga.com RBC Capital Downgrades Penumbra to Sector Perform, Raises Price Target to $374 RBC Capital analyst Shagun Singh downgrades Penumbra (NYSE:PEN) from Outperform to Sector Perform and raises the price target from $355 to $374.- benzinga.com Canaccord Genuity Downgrades Penumbra to Hold, Raises Price Target to $374 Canaccord Genuity analyst Jason Mills downgrades Penumbra (NYSE:PEN) from Buy to Hold and raises the price target from $359 to $374.
- benzinga.com Jefferies Downgrades Penumbra to Hold, Raises Price Target to $374 Jefferies analyst Matthew Taylor downgrades Penumbra (NYSE:PEN) from Buy to Hold and raises the price target from $335 to $374.
- benzinga.com Citigroup Downgrades Penumbra to Neutral, Raises Price Target to $374 Citigroup analyst Joanne Wuensch downgrades Penumbra (NYSE:PEN) from Buy to Neutral and raises the price target from $350 to $374.
benzinga.com Honeywell To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday 
benzinga.com Analyst Expectations For Penumbra's Future 
benzinga.com This JM Smucker Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - benzinga.com Baird Downgrades Penumbra to Neutral, Raises Price Target to $374 Baird analyst David Rescott downgrades Penumbra (NYSE:PEN) from Outperform to Neutral and raises the price target from $345 to $374.
- benzinga.com Truist Securities Downgrades Penumbra to Hold, Raises Price Target to $374 Truist Securities analyst Richard Newitter downgrades Penumbra (NYSE:PEN) from Buy to Hold and raises the price target from $370 to $374.
- benzinga.com Wells Fargo Downgrades Penumbra to Equal-Weight, Announces $374 Price Target Wells Fargo analyst Larry Biegelsen downgrades Penumbra (NYSE:PEN) from Overweight to Equal-Weight and announces $374 price target.
benzinga.com Wall Street Soars Near Records, AMD And ASML Jump 6%: What's Moving Markets Thursday? U.S. stocks rallied near record territory on Thursday as blowout earnings from major Wall Street firms and renewed confidence in the AI trade lifted risk appetite.
benzinga.com Penumbra, ImmunityBio, Calix, Matson And Other Big Stocks Moving Higher On Thursday